Alkermes Plc (ALKS)

34.14
0.32 0.95
NASDAQ : Health Technology
Prev Close 33.82
Open 33.88
Day Low/High 33.46 / 34.20
52 Wk Low/High 27.54 / 71.22
Volume 1.06M
Avg Volume 953.90K
Exchange NASDAQ
Shares Outstanding 155.38M
Market Cap 5.22B
EPS -1.00
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

ALKERMES INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Alkermes Plc To Contact The Firm

ALKERMES INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Alkermes Plc To Contact The Firm

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Alkermes plc ("Alkermes" or the "Company")(NASDAQ:ALKS).

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf Of Investors Of Alkermes Plc - ALKS

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf Of Investors Of Alkermes Plc - ALKS

NEW YORK, Jan. 8, 2019 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Alkermes plc ("Alkermes" or the "Company") (NASDAQ:  ALKS).

ALKERMES INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Alkermes Plc To Contact The Firm

ALKERMES INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Alkermes Plc To Contact The Firm

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Alkermes plc ("Alkermes" or the "Company")(NASDAQ:ALKS).

Investor Alert: Kaplan Fox Announces Investigation Of Alkermes Plc

Investor Alert: Kaplan Fox Announces Investigation Of Alkermes Plc

NEW YORK, Jan. 8, 2019 /PRNewswire/ -- Kaplan Fox & Kilsheimer LLP ( www.

ALKERMES INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Alkermes Plc To Contact The Firm

ALKERMES INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Alkermes Plc To Contact The Firm

NEW YORK, Jan. 7, 2019 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Alkermes plc ("Alkermes" or the "Company")(NASDAQ:ALKS).

IMPORTANT INVESTOR REMINDER: The Schall Law Firm Announces The Filing Of A Class Action Lawsuit Against Alkermes Plc And Encourages Investors With Losses In Excess Of $100,000 To Contact The Firm

IMPORTANT INVESTOR REMINDER: The Schall Law Firm Announces The Filing Of A Class Action Lawsuit Against Alkermes Plc And Encourages Investors With Losses In Excess Of $100,000 To Contact The Firm

The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Alkermes plc ("Alkermes" or "the Company") (NASDAQ: ALKS) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934...

Alkermes' Corporate Presentation To Be Webcast At The 37th Annual J.P. Morgan Healthcare Conference

Alkermes' Corporate Presentation To Be Webcast At The 37th Annual J.P. Morgan Healthcare Conference

DUBLIN, Jan. 2, 2019 /PRNewswire/ --  Alkermes plc (Nasdaq: ALKS) announced today that its corporate presentation will be webcast live at the 37 th Annual J.

Alkermes Class Action Lawsuit: Bernstein Liebhard LLP Announces That A Securities Class Action Lawsuit Has Been Filed Against Alkermes Plc - ALKS

Alkermes Class Action Lawsuit: Bernstein Liebhard LLP Announces That A Securities Class Action Lawsuit Has Been Filed Against Alkermes Plc - ALKS

NEW YORK, Dec. 28, 2018 /PRNewswire/ -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, announces that a securities class action lawsuit has been filed on behalf of those who purchased or acquired the securities of Alkermes...

EQUITY ALERT: Rosen Law Firm Files Securities Class Action Lawsuit Against Alkermes Public Limited Company - ALKS

EQUITY ALERT: Rosen Law Firm Files Securities Class Action Lawsuit Against Alkermes Public Limited Company - ALKS

Rosen Law Firm, a global investor rights law firm, announces it has filed a class action lawsuit on behalf of purchasers of the securities of Alkermes Public Limited Company (NASDAQ:ALKS) from February 17, 2017 through November 1, 2018, inclusive (the...

Alkermes Larger Than S&P 500 Component Goodyear Tire & Rubber

Alkermes Larger Than S&P 500 Component Goodyear Tire & Rubber

In the latest look at stocks ordered by largest market capitalization, Russell 3000 component Alkermes plc was identified as having a larger market cap than the smaller end of the S&P 500, for example Goodyear Tire & Rubber Co. , according to The Online Investor.

Alkermes Announces Positive Topline Results From ENLIGHTEN-2 Phase 3 Study Of ALKS 3831 In Patients With Schizophrenia

Alkermes Announces Positive Topline Results From ENLIGHTEN-2 Phase 3 Study Of ALKS 3831 In Patients With Schizophrenia

-- ALKS 3831 Met Both Co-Primary Endpoints, Demonstrating a Favorable Weight Profile Compared to Olanzapine --

EQUITY ALERT: Rosen Law Firm Announces Investigation Of Securities Claims Against Alkermes Plc - ALKS

EQUITY ALERT: Rosen Law Firm Announces Investigation Of Securities Claims Against Alkermes Plc - ALKS

Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of shareholders of Alkermes plc, Inc.

Alkermes Losses Alert: Bernstein Liebhard LLP Announces First Investigation Of Alkermes Plc - ALKS

Alkermes Losses Alert: Bernstein Liebhard LLP Announces First Investigation Of Alkermes Plc - ALKS

NEW YORK, Nov. 9, 2018 /PRNewswire/ -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, is investigating potential securities fraud claims on behalf of shareholders of Alkermes plc ("Alkermes" or the "Company") (NASDAQ: ALKS)...

Alkermes' Corporate Presentation To Be Webcast At Upcoming Healthcare Conferences

Alkermes' Corporate Presentation To Be Webcast At Upcoming Healthcare Conferences

DUBLIN, Nov. 6, 2018 /PRNewswire/ --  Alkermes plc (Nasdaq: ALKS) announced today that its corporate presentation will be webcast live at the Credit Suisse 27 th Annual Healthcare Conference on Tuesday, Nov.

Alkermes Presents New Data On ALKS 4230 At Society For Immunotherapy Of Cancer's (SITC) 33rd Annual Meeting

Alkermes Presents New Data On ALKS 4230 At Society For Immunotherapy Of Cancer's (SITC) 33rd Annual Meeting

-- Initial Clinical Data From Ongoing Monotherapy Dose-Escalation Stage of Phase 1 Study to be Presented --

Alkermes Reports On Outcome Of FDA Advisory Committee Meeting On ALKS 5461 For The Adjunctive Treatment Of Major Depressive Disorder

Alkermes Reports On Outcome Of FDA Advisory Committee Meeting On ALKS 5461 For The Adjunctive Treatment Of Major Depressive Disorder

DUBLIN, Nov. 1, 2018 /PRNewswire/ --  Alkermes plc (Nasdaq: ALKS) today announced that the Psychopharmacologic Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee, appointed by the U.

Trading In Alkermes Ordinary Shares Halted Today

Trading In Alkermes Ordinary Shares Halted Today

-- FDA Advisory Committee to Review New Drug Application for ALKS 5461 for the Adjunctive Treatment of Major Depressive Disorder --

Alkermes Announces Publication Of Phase 3 Data For ALKS 5461 For Adjunctive Treatment Of Major Depressive Disorder In Molecular Psychiatry

Alkermes Announces Publication Of Phase 3 Data For ALKS 5461 For Adjunctive Treatment Of Major Depressive Disorder In Molecular Psychiatry

-- ALKS 5461 Demonstrated Consistent Profile of Antidepressant Activity, Safety and Tolerability in Two Phase 3 Studies --

Alkermes Announces Recipients Of 3rd Annual ALKERMES INSPIRATION GRANTS®

Alkermes Announces Recipients Of 3rd Annual ALKERMES INSPIRATION GRANTS®

- Competitive Grant Program Awards $1 Million to 14 Organizations for the Development or Expansion of Programs Designed to Serve Those Affected by Mental Health or Substance Use Disorders -

Alkermes Plc Reports Third Quarter 2018 Financial Results

Alkermes Plc Reports Third Quarter 2018 Financial Results

-- Third Quarter Revenues Increased to $248.7 Million, Driven by 24% Year-Over-Year Growth of Proprietary Product Net Sales --

Alkermes Highlights Ongoing Commitment To Research And Innovation In Depression And Schizophrenia At 2018 Psych Congress

Alkermes Highlights Ongoing Commitment To Research And Innovation In Depression And Schizophrenia At 2018 Psych Congress

DUBLIN, Oct. 17, 2018 /PRNewswire/ --   Alkermes plc (Nasdaq: ALKS) today announced the presentation of 10 posters at the upcoming 31 st Annual Psych Congress (Psych Congress) in Orlando, Oct.

Alkermes To Host Conference Call To Discuss Third Quarter 2018 Financial Results

Alkermes To Host Conference Call To Discuss Third Quarter 2018 Financial Results

DUBLIN, Oct. 16, 2018 /PRNewswire/ --  Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:30 a.

Alkermes Initiates Clinical Evaluation Of Novel Immuno-Oncology Drug Candidate ALKS 4230 In Combination With PD-1 Inhibitor Pembrolizumab

Alkermes Initiates Clinical Evaluation Of Novel Immuno-Oncology Drug Candidate ALKS 4230 In Combination With PD-1 Inhibitor Pembrolizumab

-- Ongoing Phase 1 Study Expanded to Assess Safety and Anti-Tumor Activity of ALKS 4230 With Pembrolizumab in Patients With Advanced Solid Tumors --

Alkermes Announces 3rd Annual Competitive Grants Program To Support Those Affected By Mental Health And Substance Use Disorders

Alkermes Announces 3rd Annual Competitive Grants Program To Support Those Affected By Mental Health And Substance Use Disorders

-- ALKERMES Inspiration Grants® Program Will Award Up to $1 Million for the Development or Expansion of Innovative Programs --

Alkermes' Corporate Presentation To Be Webcast At The 38th Annual Canaccord Genuity Growth Conference

Alkermes' Corporate Presentation To Be Webcast At The 38th Annual Canaccord Genuity Growth Conference

DUBLIN, Aug. 1, 2018 /PRNewswire/ --  Alkermes plc (Nasdaq: ALKS) announced today that its corporate presentation will be webcast live at the 38 th Annual Canaccord Genuity Growth Conference on Wednesday, Aug.

Alkermes Plc Reports Second Quarter 2018 Financial Results

Alkermes Plc Reports Second Quarter 2018 Financial Results

-- Second Quarter Revenues Increase to $304.6 Million, Driven by License Revenues and 24% Year-Over-Year Growth of Proprietary Product Net Sales --

American Airlines Is Caught in a Downward Current, Plus 4 Other Stocks That Look Good Short

AAL, UBS, CYOU, LOGM and ALKS were all recently downgraded by TheStreet's Quant Ratings service.

TheStreet Quant Rating: D (Sell)